Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077259 · ClinicalTrials.gov registry record · Phase 2
Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00077259: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00077259 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077259, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as epothilone D work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well epothilone D works as second-line therapy in treating patients with advanced or metastatic refractory colorectal cancer.
Interventions
- DRUG epothilone D
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077259
The ClinicalTrials.gov registry entry for NCT00077259 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which epothilone D is the first listed.
NCT00077259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077259 about?
NCT00077259 is a clinical study titled "Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer". RATIONALE: Drugs used in chemotherapy such as epothilone D work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well epothilone D works as second-line therapy in treating patients with advanced or metastatic refractory co...
What is the current status of trial NCT00077259?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-10.
What interventions are being tested in trial NCT00077259?
The interventions under investigation include: epothilone D (DRUG).
Who is sponsoring clinical trial NCT00077259?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.